INCB099280

Other Medications

1 Clinical Trials

Description

INCB099280 is an experimental drug that was studied in clinical trials for certain types of advanced colorectal cancer. It was specifically investigated in patients whose tumors had a KRAS mutation. This drug was tested in combination with another experimental drug called adagrasib. The goal of the clinical trial was primarily to assess the safety and tolerability of the combination therapy and to determine the maximum tolerated dose (MTD) or recommended dose for expansion (RDE) of the combination. The trial has been terminated.

Mechanism of Action

INCB099280 is being studied in combination with adagrasib. Adagrasib targets a specific protein (KRAS G12C) that is often mutated in some cancers, including colorectal cancer. The specific mechanism of action of INCB099280 is being investigated in clinical trials, but it is intended to be used alongside adagrasib to potentially enhance its effects or target different pathways involved in tumor growth.

Side Effects

As INCB099280 is an investigational drug and the trial has been terminated Specific side effect data is limited. However As part of a Phase 1 trial The primary focus was on safety and tolerability. Patients enrolled in the trial would have experienced side effects related to both INCB099280 and adagrasib. Common side effects associated with cancer drugs in general can include fatigue Nausea Diarrhea Skin reactions And changes in blood counts. More specific side effects for this drug combination are still being evaluated.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT06039384 Phase 1
Terminated
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
United States, Italy, Spain, United Kingdom

Quick Info

CategoryOther Medications
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
781 trials
Leucovorin
Other Medications
642 trials
Paclitaxel
Other Medications
54 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials
Trifluridine
Other Medications
48 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.